Regulation of p53: A collaboration between Mdm2 and Mdmx

Oncotarget

Volumn 3, Issue 3, 2012, Pages 228-235

  Pei, Dongsheng ^a,b   Zhang, Yanping ^a,b   Zheng, Junnian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Mdm2; Mdmx; P53

Indexed keywords

MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53;

ANIMAL; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW; UBIQUITINATION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 84865675670     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.443     Document Type: Review

References (75)

1. Miliani de Marval, PL and Zhang, Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget. 2011; 2: 234-238.
2. Vousden, KH and Prives, C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137: 413-431.
3. Kruse, JP and Gu, W. Modes of p53 regulation. Cell. 2009; 137: 609-622.
4. Menendez, S, Goh, AM, Camus, S, Ng, KW, Kua, N, Badal, V and Lane, DP. MDM4 downregulates p53 transcriptional activity and response to stress during differentiation. Cell Cycle. 2011; 10: 1100-1108.
5. Fakharzadeh, SS, Trusko, SP and George, DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991; 10: 1565-1569.
6. Momand, J, Zambetti, GP, Olson, DC, George, D and Levine, AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 69: 1237-1245.
7. Joazeiro, CA and Weissman, AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell. 2000; 102: 549-552.
8. Haupt, Y, Maya, R, Kazaz, A and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387: 296-299.
9. Honda, R and Yasuda, H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene. 2000; 19: 1473-1476.
10. Kubbutat, MH, Jones, SN and Vousden, KH. Regulation of p53 stability by Mdm2. Nature. 1997; 387: 299-303.
11. Oliner, JD, Pietenpol, JA, Thiagalingam, S, Gyuris, J, Kinzler, KW and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993; 362: 857-860.
12. Itahana, K, Mao, H, Jin, A, Itahana, Y, Clegg, HV, Lindstrom, MS, Bhat, KP, Godfrey, VL, Evan, GI and Zhang, Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell. 2007; 12: 355-366.
13. Shvarts, A, Steegenga, WT, Riteco, N, van Laar, T, Dekker, P, Bazuine, M, van Ham, RC, van der Houven van Oordt, W, Hateboer, G, van der Eb, AJ and Jochemsen, AG. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996; 15: 5349-5357.
14. Zdzalik, M, Pustelny, K, Kedracka-Krok, S, Huben, K, Pecak, A, Wladyka, B, Jankowski, S, Dubin, A, Potempa, J and Dubin, G. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73. Cell Cycle. 2010; 9: 4584-4591.
15. Danovi, D, Meulmeester, E, Pasini, D, Migliorini, D, Capra, M, Frenk, R, de Graaf, P, Francoz, S, Gasparini, P, Gobbi, A, Helin, K, Pelicci, PG, Jochemsen, AG and Marine, JC. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol. 2004; 24: 5835-5843.
16. Honda, R, Tanaka, H and Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997; 420: 25-27.
17. Fang, S, Jensen, JP, Ludwig, RL, Vousden, KH and Weissman, AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000; 275: 8945-8951.
18. Pan, Y and Chen, J. MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol. 2003; 23: 5113-5121.
19. Tanimura, S, Ohtsuka, S, Mitsui, K, Shirouzu, K, Yoshimura, A and Ohtsubo, M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 1999; 447: 5-9.
20. Sharp, DA, Kratowicz, SA, Sank, MJ and George, DL. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem. 1999; 274: 38189-38196.
21. Jackson, MW and Berberich, SJ. MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol. 2000; 20: 1001-1007.
22. Stad, R, Ramos, YF, Little, N, Grivell, S, Attema, J, van Der Eb, AJ and Jochemsen, AG. Hdmx stabilizes Mdm2 and p53. J Biol Chem. 2000; 275: 28039-28044.
23. Uldrijan, S, Pannekoek, WJ and Vousden, KH. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J. 2007; 26: 102-112.
24. Poyurovsky, MV, Priest, C, Kentsis, A, Borden, KL, Pan, ZQ, Pavletich, N and Prives, C. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 2007; 26: 90-101.
25. Kawai, H, Lopez-Pajares, V, Kim, MM, Wiederschain, D and Yuan, ZM. RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res. 2007; 67: 6026-6030.
26. Linares, LK, Hengstermann, A, Ciechanover, A, Muller, S and Scheffner, M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A. 2003; 100: 12009-12014.
27. Gu, J, Kawai, H, Nie, L, Kitao, H, Wiederschain, D, Jochemsen, AG, Parant, J, Lozano, G and Yuan, ZM. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem. 2002; 277: 19251-19254.
28. Marine, JC, Francoz, S, Maetens, M, Wahl, G, Toledo, F and Lozano, G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 2006; 13: 927-934.
29. Xiong, S, Van Pelt, CS, Elizondo-Fraire, AC, Liu, G and Lozano, G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A. 2006; 103: 3226-3231.
30. Wade, M, Wang, YV and Wahl, GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010; 20: 299-309.
31. Wang, X. p53 regulation: Teamwork between RING domains of Mdm2 and MdmX. Cell Cycle. 2011; 10: 4225-4229.
32. Huang, L, Yan, Z, Liao, X, Li, Y, Yang, J, Wang, ZG, Zuo, Y, Kawai, H, Shadfan, M, Ganapathy, S and Yuan, ZM. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci U S A. 2011; 108: 12001-12006.
33. Pant, V, Xiong, S, Iwakuma, T, Quintas-Cardama, A and Lozano, G. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A. 2011; 108: 11995-12000.
34. Stad, R, Little, NA, Xirodimas, DP, Frenk, R, van der Eb, AJ, Lane, DP, Saville, MK and Jochemsen, AG. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2001; 2: 1029-1034.
35. Migliorini, D, Danovi, D, Colombo, E, Carbone, R, Pelicci, PG and Marine, JC. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J Biol Chem. 2002; 277: 7318-7323.
36. Wang, YV, Wade, M, Wong, E, Li, YC, Rodewald, LW and Wahl, GM. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci U S A. 2007; 104: 12365-12370.
37. Linke, K, Mace, PD, Smith, CA, Vaux, DL, Silke, J and Day, CL. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 2008; 15: 841-848.
38. Barak, Y, Juven, T, Haffner, R and Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993; 12: 461-468.
39. Perry, ME, Piette, J, Zawadzki, JA, Harvey, D and Levine, AJ. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci U S A. 1993; 90: 11623-11627.
40. Carter, S, Bischof, O, Dejean, A and Vousden, KH. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol. 2007; 9: 428-435.
41. Li, M, Brooks, CL, Wu-Baer, F, Chen, D, Baer, R and Gu, W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 2003; 302: 1972-1975.
42. Stommel, JM and Wahl, GM. Accelerated MDM2 autodegradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004; 23: 1547-1556.
43. de Graaf, P, Little, NA, Ramos, YF, Meulmeester, E, Letteboer, SJ and Jochemsen, AG. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem. 2003; 278: 38315-38324.
44. Kawai, H, Wiederschain, D, Kitao, H, Stuart, J, Tsai, KK and Yuan, ZM. DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem. 2003; 278: 45946-45953.
45. Sabbatini, P and McCormick, F. MDMX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol. 2002; 21: 519-525.
46. Lee, JT and Gu, W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 2010; 17: 86-92.
47. Kostic, M, Matt, T, Martinez-Yamout, MA, Dyson, HJ and Wright, PE. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J Mol Biol. 2006; 363: 433-450.
48. Ye, Y and Rape, M. Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol. 2009; 10: 755-764.
49. Saville, MK, Sparks, A, Xirodimas, DP, Wardrop, J, Stevenson, LF, Bourdon, JC, Woods, YL and Lane, DP. Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem. 2004; 279: 42169-42181.
50. David, Y, Ternette, N, Edelmann, MJ, Ziv, T, Gayer, B, Sertchook, R, Dadon, Y, Kessler, BM and Navon, A. E3 Ligases Determine the Ubiquitination Site and Conjugate Type by Enforcing Specificity on E2 Enzymes. J Biol Chem. 2011;
51. Cheng, Q and Chen, J. Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle. 2010; 9: 472-478.
52. Inuzuka, H, Fukushima, H, Shaik, S and Wei, W. Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction. Oncotarget. 2010; 1: 685-690.
53. Meek, DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer. 2009; 9: 714-723.
54. Waning, DL, Lehman, JA, Batuello, CN and Mayo, LD. Controlling the Mdm2-Mdmx-p53 Circuit. Pharmaceuticals (Basel). 2010; 3: 1576-1593.
55. Cheng, Q, Chen, L, Li, Z, Lane, WS and Chen, J. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J. 2009; 28: 3857-3867.
56. Chen, L, Gilkes, DM, Pan, Y, Lane, WS and Chen, J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 2005; 24: 3411-3422.
57. Okamoto, K, Kashima, K, Pereg, Y, Ishida, M, Yamazaki, S, Nota, A, Teunisse, A, Migliorini, D, Kitabayashi, I, Marine, JC, Prives, C, Shiloh, Y, Jochemsen, AG and Taya, Y. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol. 2005; 25: 9608-9620.
58. LeBron, C, Chen, L, Gilkes, DM and Chen, J. Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-EMBO J. 2006; 25: 1196-1206.
59. Pereg, Y, Lam, S, Teunisse, A, Biton, S, Meulmeester, E, Mittelman, L, Buscemi, G, Okamoto, K, Taya, Y, Shiloh, Y and Jochemsen, AG. Differential roles of ATM-and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol Cell Biol. 2006; 26: 6819-6831.
60. Zhang, X, Lin, L, Guo, H, Yang, J, Jones, SN, Jochemsen, A and Lu, X. Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response. Cancer Res. 2009; 69: 7960-7968.
61. Lu, X, Nguyen, TA, Zhang, X and Donehower, LA. The Wip1 phosphatase and Mdm2: cracking the "Wip" on p53 stability. Cell Cycle. 2008; 7: 164-168.
62. Wang, YV, Leblanc, M, Wade, M, Jochemsen, AG and Wahl, GM. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell. 2009; 16: 33-43.
63. Li, B, Cheng, Q, Li, Z and Chen, J. p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors. Cell Cycle. 2010; 9: 1411-1420.
64. Azmi, AS, Banerjee, S, Ali, S, Wang, Z, Bao, B, Beck, FW, Maitah, M, Choi, M, Shields, TF, Philip, PA, Sarkar, FH and Mohammad, RM. Network modeling of MDM2 inhibitoroxaliplatin combination reveals biological synergy in wtp53 solid tumors. Oncotarget. 2011; 2: 378-392.
65. Vassilev, LT, Vu, BT, Graves, B, Carvajal, D, Podlaski, F, Filipovic, Z, Kong, N, Kammlott, U, Lukacs, C, Klein, C, Fotouhi, N and Liu, EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303: 844-848.
66. Apontes, P, Leontieva, OV, Demidenko, ZN, Li, F and Blagosklonny, MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011; 2: 222-233.
67. Rao, B, van Leeuwen, IM, Higgins, M, Campbel, J, Thompson, AM, Lane, DP and Lain, S. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget. 2010; 1: 639-650.
68. Marine, JC and Lozano, G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 2010; 17: 93-102.
69. Bernal, F, Wade, M, Godes, M, Davis, TN, Whitehead, DG, Kung, AL, Wahl, GM and Walensky, LD. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell. 2010; 18: 411-422.
70. Joseph, TL, Madhumalar, A, Brown, CJ, Lane, DP and Verma, CS. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle. 2010; 9: 1167-1181.
71. Popowicz, GM, Czarna, A, Wolf, S, Wang, K, Wang, W, Domling, A and Holak, TA. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle. 2010; 9: 1104-1111.
72. Joseph, TL, Lane, D and Verma, CS. Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein. Cell Cycle. 2010; 9: 4560-4568.
73. Yang, Y, Li, CC and Weissman, AM. Regulating the p53 system through ubiquitination. Oncogene. 2004; 23: 2096-2106.
74. Yang, Y, Ludwig, RL, Jensen, JP, Pierre, SA, Medaglia, MV, Davydov, IV, Safiran, YJ, Oberoi, P, Kenten, JH, Phillips, AC, Weissman, AM and Vousden, KH. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell. 2005; 7: 547-559.
75. Linares, LK, Kiernan, R, Triboulet, R, Chable-Bessia, C, Latreille, D, Cuvier, O, Lacroix, M, Le Cam, L, Coux, O and Benkirane, M. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol. 2007; 9: 331-338.